An Allorion Therapeutics (Guangzhou) Co. Ltd. patent discloses aminoheteroaryl CDK4/cyclin D1 inhibitors reported to be useful for the treatment of cancer.
Celgene Corp. has identified substituted imidazopyrazine compounds characterized as interleukin-1 receptor-associated kinase 3 (IRAK-3; IRAK-M) ligands and thus reported to be useful for the treatment of cancer, autoimmune diseases and inflammatory disorders.
Quinoxaline derivatives acting as phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) and/or (E545K mutant) inhibitors have been described in a Black Diamond Therapeutics Inc. patent.
Shanghai Apeiron Biotechnology Co. Ltd. has patented new protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Researchers from Chonnam National University presented novel a doxycycline (Doxy)-inducible gene switch system in attenuated Salmonella typhimurium, one of the bacterial strains that has been previously shown to selectively colonize and multiply in tumors, leading to oxygen deprivation, excessive nutrient leakage, and an antitumor immune response.
Survival in metastatic breast cancer has increased in recent years, but 5-year survival rates remain below 50% and the mechanisms of spreading remain to be elucidated. An emerging strategy to inhibit the progression of tumors consists of acting on tumor-associated macrophages to displace them from an M2-like phenotype to an M1-like phenotype.
Several metabolic alterations, including a preferential use of aerobic glycolysis, facilitate autonomous proliferation and survival of tumor cells. Although previous research suggested that active glycolysis in tumor cells is closely linked to genetic alterations, the underlying regulatory mechanisms remained unknown.
Researchers from University of California Los Angeles and affiliated organizations published data from a study that aimed to identify novel surface proteins that are highly and selectively expressed in tumors and could serve as targets for chimeric antigen receptor (CAR) T-cell therapies for the treatment of melanoma.
The aryl hydrocarbon receptor (AhR) is a transcription factor that modulates the activity of tumor and immune cells, hence targeting AhR may represent a feasible option for cancer immunotherapy. Researchers from the Institute of Materia Medica of Beijing and collaborators recently reported on the discovery and synthesis of a novel series of AhR antagonists derived from Salvia miltiorrhiza Bunge intended to be used in cancer immunotherapy.
RSS
.webp?height=488&t=1708619318&width=650 "Co-culture that shows the CAR T-cell clusters attacking the tumor cells (in green)")
